Regencell Bioscience
16 hedge funds and large institutions have $9.79M invested in Regencell Bioscience in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
14% more funds holding
Funds holding: 14 → 16 (+2)
0.01% less ownership
Funds ownership: 0.14% → 0.13% (-0.01%)
17% less capital invested
Capital invested by funds: $11.8M → $9.79M (-$2M)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
24% less call options, than puts
Call options by funds: $1.26M | Put options by funds: $1.66M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$662K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$556K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$415K |
| 4 |
VA
Vident Advisory
Alpharetta,
Georgia
|
+$259K |
| 5 |
Jane Street
New York
|
+$152K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$888K |
| 2 |
Squarepoint
New York
|
-$697K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$579K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$533K |
| 5 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$222K |
RGC Hedge Fund Activity: Q3 2025 in Review
16 of the 7,643 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q3 2025, worth a combined $9.79M — down 17% from $11.8M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new RGC positions and 5 closed out — a net gain of 2 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Discovery Capital Management, opening a new position worth an estimated $662K. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $888K sold.
- 16 institutional investors held Regencell Bioscience (RGC) as of Q3 2025, up from 14 in Q2 2025.
- Funds reported $9.79M of Regencell Bioscience stock for Q3 2025, down 17% quarter-over-quarter.
- 7 funds opened new Regencell Bioscience positions in Q3 2025 and 5 closed out, a net change of +2 holders.
- The largest Regencell Bioscience buyer in Q3 2025 was Discovery Capital Management, an estimated $662K added.
- The largest Regencell Bioscience seller in Q3 2025 was Schonfeld Strategic Advisors, an estimated $888K sold.
Based on aggregated 13F filings for Q3 2025.